Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Cellular Biomedicine Group (NASDAQ:CBMG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Valuation and Earnings
This table compares Brainstorm Cell Therapeutics and Cellular Biomedicine Group’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Brainstorm Cell Therapeutics||N/A||N/A||-$4.95 million||($0.26)||-11.77|
|Cellular Biomedicine Group||$340,000.00||1,016.33||-$25.49 million||($1.78)||-10.55|
Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Cellular Biomedicine Group. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Cellular Biomedicine Group, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Brainstorm Cell Therapeutics has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, Cellular Biomedicine Group has a beta of 3.58, indicating that its share price is 258% more volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Brainstorm Cell Therapeutics and Cellular Biomedicine Group, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Brainstorm Cell Therapeutics||0||0||2||0||3.00|
|Cellular Biomedicine Group||0||1||1||0||2.50|
Brainstorm Cell Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 226.80%. Cellular Biomedicine Group has a consensus target price of $38.00, indicating a potential upside of 102.34%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Cellular Biomedicine Group.
This table compares Brainstorm Cell Therapeutics and Cellular Biomedicine Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Brainstorm Cell Therapeutics||N/A||-101.86%||-59.62%|
|Cellular Biomedicine Group||-13,988.39%||-44.62%||-41.84%|
Insider & Institutional Ownership
11.4% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 8.8% of Cellular Biomedicine Group shares are held by institutional investors. 22.6% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 8.3% of Cellular Biomedicine Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Brainstorm Cell Therapeutics beats Cellular Biomedicine Group on 8 of the 12 factors compared between the two stocks.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing; and Novartis to manufacture and supply the CAR-T cell therapy KymriahÂ. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in Cupertino, California.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.